These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12805439)

  • 1. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions.
    Duraiswamy J; Burrows JM; Bharadwaj M; Burrows SR; Cooper L; Pimtanothai N; Khanna R
    J Virol; 2003 Jul; 77(13):7401-10. PubMed ID: 12805439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia.
    Burrows JM; Bromham L; Woolfit M; Piganeau G; Tellam J; Connolly G; Webb N; Poulsen L; Cooper L; Burrows SR; Moss DJ; Haryana SM; Ng M; Nicholls JM; Khanna R
    J Virol; 2004 Jul; 78(13):7131-7. PubMed ID: 15194789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
    Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
    Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan.
    Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC
    J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleotide sequences and functions of the Epstein-Barr virus latent membrane protein 1 genes isolated from salivary gland lymphoepithelial carcinomas.
    Jen KY; Higuchi M; Cheng J; Li J; Wu LY; Li YF; Lin HL; Chen Z; Gurtsevitch V; Fujii M; Saku T
    Virus Genes; 2005 Mar; 30(2):223-35. PubMed ID: 15744579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
    Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
    Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
    Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
    Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
    Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
    Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid changes in functional domains of latent membrane protein 1 of Epstein-Barr virus in nasopharyngeal carcinoma of southern China and Taiwan: prevalence of an HLA A2-restricted 'epitope-loss variant'.
    Lin JC; Cherng JM; Lin HJ; Tsang CW; Liu YX; Lee SP
    J Gen Virol; 2004 Jul; 85(Pt 7):2023-2034. PubMed ID: 15218188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine.
    Duraiswamy J; Bharadwaj M; Tellam J; Connolly G; Cooper L; Moss D; Thomson S; Yotnda P; Khanna R
    Cancer Res; 2004 Feb; 64(4):1483-9. PubMed ID: 14973049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
    Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
    Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of LMP1 variants of EBV in Southern Thailand: evidence for strain-associated T-cell tropism and pathogenicity.
    Saechan V; Mori A; Mitarnun W; Settheetham-Ishida W; Ishida T
    J Clin Virol; 2006 Jun; 36(2):119-25. PubMed ID: 16616610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.